Skip to main content

IOVA

Stock
Health Care
Biotechnology

Performance overview

IOVA Price
Price Chart

Forward-looking statistics

Beta
1.24
Risk
76.86%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

Company info

SectorHealth Care
IndustryBiotechnology
Employees518
Market cap$2.2B

Fundamentals

Enterprise value$268.4M
Revenue$212.7M
Revenue per employee
Profit margin-176.49%
Debt to equity7.00

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$1.22
Dividend per share
Revenue per share$0.70
Avg trading volume (30 day)$21M
Avg trading volume (10 day)$19M
Put-call ratio

Macro factor sensitivity

Growth+3.4
Credit+6.0
Liquidity-1.7
Inflation+0.9
Commodities+1.9
Interest Rates-2.3

Valuation

Dividend yield0.00%
PEG Ratio-2.13
Price to sales2.75
P/E Ratio-2.13
Enterprise Value to Revenue1.26
Price to book0.76

Upcoming events

Next earnings dayMay 9, 2025
Next dividend day
Ex. dividend day

News

Iovance's Q1 Earnings & Sales Miss, Stock Slides 39% on '25 View Cut

IOVA reports dismal first-quarter results. The share price plunges after the company significantly lowers its 2025 sales guidance.

Zacks Investment Research (May 9, 2025)
Top 3 Health Care Stocks That Are Set To Fly This Month

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Benzinga (March 26, 2025)
Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market

The FDA wrapped up 2024 with 50 new drug approvals, clearing a wave of long-awaited treatments. Meanwhile, Transcarent will take Accolade private.

CNBC (January 8, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free